4-methoxy-5,6-dihydro-2H-pyrane | 135950-25-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-methoxy-5,6-dihydro-2H-pyrane
• 英文别名: 4-methoxy-3,4-dihydro-2H-pyran；4,5-dihydro-4-methoxypyran；MTHP；4-Methoxydihydropyran
• CAS: 135950-25-3
• 化学式: C₆H₁₀O₂
• 分子量: 114.144
• InChiKey: OTWQGQGARJLQON-UHFFFAOYSA-N

物化性质

• 沸点：
  157.9±29.0 °C(Predicted)
• 密度：
  0.98±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-methoxy-5,6-dihydro-2H-pyrane 在 pig liver esterase enzyme 作用下， 以 丙酮 为溶剂， 生成 3-[(E)-4-(4-Methoxy-tetrahydro-pyran-2-yloxy)-but-2-enyl]-pentanedioic acid monomethyl ester
  参考文献：
  名称：

  猪肝酯酶对3-烷基单取代戊二酸二烷基酯的对映选择性水解：结构-光学纯度关系

  摘要：

  用猪肝酯酶水解3-单取代的戊二酸二烷基酯，得到相应的手性半酯。从具有更疏水性质的前手性底物获得了更高光学纯度的合成上有用的半酯。

  DOI：

  10.1016/s0040-4039(00)80391-3

文献信息

• [EN] NITROGEN- HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS<br/>[FR] COMPOSÉS AZOTÉS HÉTÉROCYCLIQUES CONVENANT COMME INHIBITEURS DE LA PHOSPHODIESTÉRASE 10
  申请人：AMGEN INC

  公开号：WO2011143129A1

  公开（公告）日：2011-11-17

  Aryl- and heteroaryl-nitrogen heterocyclic compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDEIO, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like.

  芳基和杂环氮杂环化合物，以及含有它们的组合物，以及制备这类化合物的方法。本文还提供了通过抑制PDEIO治疗可治疗的疾病或疾病的方法，如肥胖症，非胰岛素依赖型糖尿病，精神分裂症，亨廷顿病，躁郁症，强迫症等。
• Strain of streptomyces
  申请人：SANKYO COMPANY LIMITED

  公开号：US20030069204A1

  公开（公告）日：2003-04-10

  The present invention relates to ester, ether and N-alkylcarbamoyl derivatives of compound (Ia) and pharmaceutically acceptable salts thereof. These compounds exhibit excellent antibacterial activity and are useful for the treatment or prevention of bacterial infections. 1 (wherein R 1 is a hydrogen atom or a methyl group; R 2 a is a hydrogen atom, a protecting group for a hydroxy group, or a methyl group; R 3 is a hydrogen atom or a protecting group for a hydroxy group; R 4 a is a hydrogen atom, a hydroxy group or a protected hydroxy group; R 5 is a hydrogen atom or a protecting group for a hydroxy group; and X is a methylene group or a sulfur atom). The invention also includes compounds which are related to the aforeidentified compounds.

  本发明涉及化合物（Ia）的酯、醚和N-烷基氨基甲酰衍生物及其药学上可接受的盐。这些化合物表现出优异的抗菌活性，并可用于治疗或预防细菌感染。其中，R1是氢原子或甲基基团；R2a是氢原子、羟基保护基或甲基基团；R3是氢原子或羟基保护基；R4a是氢原子、羟基或受保护的羟基；R5是氢原子或羟基保护基；X是亚甲基或硫原子。本发明还包括与上述化合物相关的化合物。
• ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS
  申请人：Allen Jennifer R.

  公开号：US20110306590A1

  公开（公告）日：2011-12-15

  Aryl- and heteroaryl-nitrogen heterocyclic compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like.

  提供了芳基和杂芳基氮杂环化合物及含有它们的组合物，以及制备这些化合物的方法。本文还提供了治疗可通过抑制PDE10治疗的疾病或疾病的方法，例如肥胖症，非胰岛素依赖性糖尿病，精神分裂症，亨廷顿病，双相障碍，强迫症等。
• THIAZOLIDINONE COMPOUNDS OR ANGINA PECTORIS REMEDY OR PREVENTIVE CONTAINING THE SAME AS ACTIVE INGREDIENT
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0798298A1

  公开（公告）日：1997-10-01

  [Constitution] Thiazolidinone compounds having the general formula: [wherein W represents a sulfur atom or an oxygen atom, and X represents a group having the formula: -N(R1)-; or X represents a sulfur atom or an oxygen atom, and W represents a group having the formula: -N(R1)-; R1 represents a hydrogen atom, an alkyl group or a substituted alkyl group; R2 and R3 may be the same or different and each represents a hydrogen atom, an alkyl group, a substituted alkyl group, an aryl group or a 5- or 6-membered aromatic heterocyclic group; R4 represents a hydrogen atom, an alkyl group or a substituted C1-C4 alkyl group; R5 represents a substituted cycloalkyl group optionally containing a nitrogen atom [said substituent is essentially a group having the formula: -B-ONO2 (wherein B represents a single bond or an alkylene group) and optionally an alkyl group]; and A represents a single bond or an alkylene group; ] or pharmacologically acceptable salts thereof. [Effect] The compounds have an excellent anti-angina pectoris action and are useful as a therapeutic or preventing agent for angina pectoris.

  [组织结构］ 通式如下的噻唑烷酮化合物 [其中 W 代表硫原子或氧原子，X 代表具有以下通式的基团：-N(R1)-；或 X 代表硫原子或氧原子，而 W 代表具有以下式子的基团：-N(R1)-； R1 代表氢原子、烷基或取代烷基； R2 和 R3 可以相同或不同，各自代表氢原子、烷基、取代烷基、芳基或 5 或 6 元芳香杂环基团； R4 代表氢原子、烷基或取代的 C1-C4 烷基； R5 代表可选含有一个氮原子的取代环烷基[所述取代基基本上是具有以下式子的基团：-B-ONO2（其中 B 代表单键或亚烷基）和可选的烷基]；和 A 代表单键或亚烷基； ]或其药理学上可接受的盐。 效果 这些化合物具有很好的抗心绞痛作用，可作为心绞痛的治疗剂或预防剂。
• Novel antibacterial compounds
  申请人：Sankyo Company, Limited

  公开号：EP1319406A1

  公开（公告）日：2003-06-18

  The use of compounds of formula (I), defined herein, or pharmaceutically acceptable salts thereof, or of pharmaceutically acceptable esters, ethers or N-alkylcarbamoyl derivatives of compounds of formula (Ia), defined herein, or phamaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prevention of a bacterial infection caused by Mycobacterium bacteria is disclosed. The invention further provides the use of capuramycin in the manufacture of a medicament for the treatment or prevention of a bacterial infection caused by Mycobacterium tuberculosis bacteria.

  本发明公开了本文定义的式(I)化合物或其药学上可接受的盐，或本文定义的式(Ia)化合物或其药学上可接受的盐的药学上可接受的酯、醚或N-烷基氨基甲酰基衍生物在制造治疗或预防由分枝杆菌引起的细菌感染的药物中的用途。本发明进一步提供了卡曲霉素在制造治疗或预防结核分枝杆菌引起的细菌感染的药物中的用途。